256 related articles for article (PubMed ID: 9210625)
1. Effects of simvastatin, pentoxifylline and spironolactone on hepatic fibrosis and portal hypertension in rats with bile duct ligation.
Oberti F; Pilette C; Rifflet H; Maïga MY; Moreau A; Gallois Y; Girault A; le Bouil A; Le Jeune JJ; Saumet JL; Feldmann G; Calès P
J Hepatol; 1997 Jun; 26(6):1363-71. PubMed ID: 9210625
[TBL] [Abstract][Full Text] [Related]
2. Prevention of portal hypertension by propranolol and spironolactone in rats with bile duct ligation.
Oberti F; Rifflet H; Maïga MY; Pilette C; Gallois Y; Douay O; Le Jeune JJ; Saumet JL; Calès P
J Hepatol; 1997 Jan; 26(1):167-73. PubMed ID: 9148008
[TBL] [Abstract][Full Text] [Related]
3. Bilioenteric anastomosis reverses hyperkinetic circulation in bile duct-ligated cirrhotic rats.
Jalink D; Urbanski SJ; Lee SS
J Hepatol; 1996 Dec; 25(6):924-31. PubMed ID: 9007722
[TBL] [Abstract][Full Text] [Related]
4. Long-term administration of PGE1 increases liver fibrosis and collateral blood flow in bile-duct-ligated rats.
Fort J; Pilette C; Oberti F; Veal N; Gallois Y; Douay O; Calès P
J Hepatol; 1999 Jan; 30(1):70-6. PubMed ID: 9927152
[TBL] [Abstract][Full Text] [Related]
5. Early colchicine administration reduces hepatic fibrosis and portal hypertension in rats with bile duct ligation.
Poo JL; Feldmann G; Moreau A; Gaudin C; Lebrec D
J Hepatol; 1993 Aug; 19(1):90-4. PubMed ID: 8301049
[TBL] [Abstract][Full Text] [Related]
6. Experimental colitis in rats with portal hypertension and liver disease.
Ackerman Z; Karmeli F; Cohen P; Rachmilewitz D
Inflamm Bowel Dis; 2003 Jan; 9(1):18-24. PubMed ID: 12656133
[TBL] [Abstract][Full Text] [Related]
7. Extrahepatic angiogenesis hinders recovery of portal hypertension and collaterals in rats with cirrhosis resolution.
Hsu SJ; Tsai MH; Chang CC; Hsieh YH; Huang HC; Lee FY; Chuang CL; Hou MC; Lee SD
Clin Sci (Lond); 2018 Mar; 132(6):669-683. PubMed ID: 29449343
[TBL] [Abstract][Full Text] [Related]
8. Hemodynamic and antifibrotic effects of losartan in rats with liver fibrosis and/or portal hypertension.
Croquet V; Moal F; Veal N; Wang J; Oberti F; Roux J; Vuillemin E; Gallois Y; Douay O; Chappard D; Calès P
J Hepatol; 2002 Dec; 37(6):773-80. PubMed ID: 12445418
[TBL] [Abstract][Full Text] [Related]
9. Effects of the administration of pentoxifylline and prednisolone on the evolution of portal fibrogenesis secondary to biliary obstruction-an experimental study in growing animals.
Andrade Wde C; Tannuri U; da Silva LF; Alves VA
J Pediatr Surg; 2009 Nov; 44(11):2071-7. PubMed ID: 19944210
[TBL] [Abstract][Full Text] [Related]
10. Effects of ritanserin, a selective and specific S2-serotonergic antagonist, on portal pressure and splanchnic hemodynamics in rats with long-term bile duct ligation.
Fernández M; Pizcueta P; García-Pagán JC; Feu F; Cirera I; Bosch J; Rodés J
Hepatology; 1993 Aug; 18(2):389-93. PubMed ID: 8340068
[TBL] [Abstract][Full Text] [Related]
11. Pentoxifylline, a drug with rheological effects, decreases portal pressure in an experimental model of cirrhosis.
Sánchez S; Albornoz L; Bandi JC; Gerona S; Mastai R
Eur J Gastroenterol Hepatol; 1997 Jan; 9(1):27-31. PubMed ID: 9031895
[TBL] [Abstract][Full Text] [Related]
12. Role of cirrhosis in the hemodynamic response to hemorrhage in portal hypertension.
Burns RC; Wu Y; Sitzmann JV
Surgery; 1995 May; 117(5):488-93. PubMed ID: 7740418
[TBL] [Abstract][Full Text] [Related]
13. Effects of portacaval shunting on hyperdynamic circulation in bile duct-ligated cirrhotic rats.
Wong J; Zhang Y; Lee SS
J Hepatol; 1997 Feb; 26(2):369-75. PubMed ID: 9059959
[TBL] [Abstract][Full Text] [Related]
14. Antifibrotic and hemodynamic effects of the early and chronic administration of octreotide in two models of liver fibrosis in rats.
Fort J; Oberti F; Pilette C; Veal N; Gallois Y; Douay O; Rousselet MC; Rosenbaum J; Calès P
Hepatology; 1998 Dec; 28(6):1525-31. PubMed ID: 9828216
[TBL] [Abstract][Full Text] [Related]
15. Capsaicin treatment blocks development of hyperkinetic circulation in portal hypertensive and cirrhotic rats.
Lee SS; Sharkey KA
Am J Physiol; 1993 May; 264(5 Pt 1):G868-73. PubMed ID: 8498513
[TBL] [Abstract][Full Text] [Related]
16. Soluble guanylyl cyclase stimulation and phosphodiesterase-5 inhibition improve portal hypertension and reduce liver fibrosis in bile duct-ligated rats.
Brusilovskaya K; Königshofer P; Lampach D; Szodl A; Supper P; Bauer D; Beer A; Stift J; Timelthaler G; Oberhuber G; Podesser BK; Seif M; Zinober K; Rohr-Udilova N; Trauner M; Reiberger T; Schwabl P
United European Gastroenterol J; 2020 Dec; 8(10):1174-1185. PubMed ID: 32878579
[TBL] [Abstract][Full Text] [Related]
17. The Impact of Spironolactone on the Severity of Portal-Systemic Collaterals and Hepatic Encephalopathy in Cirrhotic Rats.
Hsu SJ; Wang SS; Huo TI; Lee FY; Huang HC; Chang CC; Hsin IF; Ho HL; Lin HC; Lee SD
J Pharmacol Exp Ther; 2015 Oct; 355(1):117-24. PubMed ID: 26260462
[TBL] [Abstract][Full Text] [Related]
18. Effects of long-term administration of interferon alpha in two models of liver fibrosis in rats.
Fort J; Pilette C; Veal N; Oberti F; Gallois Y; Douay O; Rosenbaum J; Calès P
J Hepatol; 1998 Aug; 29(2):263-70. PubMed ID: 9722208
[TBL] [Abstract][Full Text] [Related]
19. Enoxaparin does not ameliorate liver fibrosis or portal hypertension in rats with advanced cirrhosis.
Fortea JI; Zipprich A; Fernandez-Mena C; Puerto M; Bosoi CR; Almagro J; Hollenbach M; Bañares J; Rodríguez-Sánchez B; Cercenado E; Clément MA; Rose CF; Bañares R; Vaquero J; Ripoll C
Liver Int; 2018 Jan; 38(1):102-112. PubMed ID: 28665498
[TBL] [Abstract][Full Text] [Related]
20. Hemodynamic and antifibrotic effects of a selective liver nitric oxide donor V-PYRRO/NO in bile duct ligated rats.
Moal F; Veal N; Vuillemin E; Barrière E; Wang J; Fizanne L; Oberti F; Douay O; Gallois Y; Bonnefont-Rousselot D; Rousselet MC; Calès P
World J Gastroenterol; 2006 Nov; 12(41):6639-45. PubMed ID: 17075977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
